iOncologi has acquired TargImmune Therapeutics, a biotechnology company specializing in novel tumor targeted immunotherapies.

This strategic acquisition significantly enhances iOncologi's capabilities in developing cutting-edge immunotherapies for solid tumors.

As part of the transaction, iOncologi, Inc. and TargImmune Therapeutics executed a share purchase agreement, resulting in iOncologi acquiring at least 99 percent of TargImmune's shares, warrants, and options. Following the acquisition, TargImmune will continue to operate in Basel, Switzerland, as a wholly owned subsidiary of iOncologi, Inc.

This structure ensures the seamless continuation of TargImmune's research into novel tumor-targeted RNA therapies while benefiting from iOncologi's expanded resources and strategic vision.

"This acquisition represents a pivotal moment for iOncologi as we continue to push the boundaries of immunotherapy for solid tumors. TargImmune's pioneering approaches perfectly align with our mission to develop transformative cancer therapies. By integrating two incredibly talented and highly experienced drug development teams, we are well-positioned to accelerate innovation and bring novel treatments to patients with limited therapeutic options," said Dr. Edgardo Rodriguez-Lebron, CEO, iOncologi.

The acquisition aligns with iOncologi's broader strategy to expand its therapeutic pipeline, leverage next-generation RNA-based immunotherapies, and drive innovation in oncology.